Shineway performed well in 23H1, but there're short-term headwinds such as VBP/anti-corruption. We remain optimistic due to policy support and the future high growth of TCM formula granules business.
Boomeranged on Tue, 7 Nov 2023 08:58
Shineway's 23Q1-Q3 turnover growth decreased to 21.9% YoY due to big decrease in growth of injection products/TCM formula granule, which is in line with our analysis in this insight. The anti-corruption campaign and demand decrease for COVID-19 products were the main reasons, so 23H2 performance growth will be lower than 23H1, but we remain optimistic that 2023 revenue growth is higher than 2022.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.